, /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced it has expanded its capital base by .6 billion to support the creation and development of an estimated 25 breakthrough companies in human health, sustainability, and artificial intelligence. Flagship has raised .
6 billion into Fund VIII, in addition to side funds that include sector-specific strategic partnerships totaling . This brings the total capital raised by Flagship into its funds since 2021 to . "At Flagship, we focus on pioneering original science, and on harnessing the ingenuity needed to invent transformative technologies and companies that improve human health as well as the sustainability of our planet," said , Ph.
D., Founder and CEO of Flagship Pioneering. "Our unique approach to making breakthrough scientific discoveries, combined with our track record of founding, building, and scaling companies, has led to the creation and growth of more than 100 biotechnology companies in just over two decades.
And I believe Flagship's most generative, impactful days lie ahead of us." "Over the past six years, Flagship has also pioneered AI-enabled platforms that transform drug discovery, speed up the drug development process and gain new insights into human health and sustainability," Afeyan added. "By leveraging the power and potential of generative AI, we're embracing a future in which companies are created and expanded in ways we have not previously experienced, with the prospect f.